3rd Quarter 2025 Financial Results

3rdQuarter 2025

Financial Results

11stNovember 2025

Opening Remarks Aloke Lohia GCEO

IVL by Regions

IVL Adjusted EBITDA ($M) and Adjusted EBITDA Margin (%)

-15%

QoQ 3Q25 vs 2Q25

427

-35%

YoY 3Q25 vs 3Q24

1

80

358

75

75

330

307

276

279

(15%)

225

(13%)

2683

(12%)

68 194

(8%)

Brent oil

($/bbl)

191

(10%)

28

(4%)

40

(6%)

29

(4%)

102

(9%)

(10)

93

(8%)

1

18

(2%)

75

(7%)

(8)

99

(9%)

(11)

25

(1%)

71

(11%)

(11)

AMERS

EMEA

Asia

Corporate

3Q24 4Q24 1Q25 2Q25 3Q25

Reported EBITDA ($M) 374 299 275 280 258

Note: (1) Some minor reclassifications of EBITDA are done between Specialty Chemicals, Integrated PET and Fibers in 1Q25 to reflect business performance correctly. Since the impact is not material hence prior periods reclassifications are not done;

(2) Starting from 1Q25, we have normalized weather-related disruptions into our adjusted financials, and all the prior periods are restated accordingly to reflect the correct business performances without weather-related events Source: IVL Analysis

© Indorama Ventures 4

Asset Optimizations since 2024-3Q25

2.7 MMT

Capacity

rationalization

$200 M+

Expected proceeds

from land

and property sales in 2026

$1.16 B

Impairments

(including severance and other expenses)

$126 M

LTM3Q25

fixed cost reduction

• Rotterdam PET/PTA

• Portugal PTA

• Canada PTA

• Surfactant Australia

• Wellman

• Others

© Indorama Ventures 5

Management Actions to reduce Fixed Costs

IVL Fixed Costs ($B)

Note: Excludes FC of Shutdown sites and one off costs

© Indorama Ventures 6

IVL Net Debt and Interest Benchmark Cost

Net Debt1($B)

5.28

4.88

4.37

6.9

7.2

6.7

7.0

7.0

1.14

2022 2023 2024 9M25

Note: (1) Net debt before currency translation and lease impacts to reflect underlying debt movement; (2) 2022 and 2023 includes $150M deferred payment liability for Oxiteno paid in 2024

Source: IVL Analysis

© Indorama Ventures 7

Focus on Working Capital

Net Working Capital ($M)

90

89

93

87

2,185

1,439

1,186

1,106

3Q22 3Q23 3Q24 3Q25

Source: IVL Analysis

© Indorama Ventures 8

IVL by Segments

IVL Adjusted EBITDA ($M) and Adjusted EBITDA Margin (%)

-15%

QoQ 3Q25 vs 2Q25

427

-35%

YoY 3Q25 vs 3Q24

Fibers

Indovinya

CPET & Indovida Corporate

48

(6%)

103

(16%)

358

33

(4%)

81

(13%)

276

47

(6%)

330

47

(6%)

75

(13%)

89

(14%)

279

31

(4%)

78

(12%)

286

(11%)

243

(10%)

147

(6%)

219

(10%)

182

(8%)

(10)

1

(8)

(11)

(11)

3Q24 4Q24 1Q25 2Q25 3Q25

Reported EBITDA ($M) 374 299 275 280 258

Note: (1) Total Reported and Adjusted EBITDA includes holding EBITDA which includes corporate expenses;

1. Some minor reclassifications of EBITDA are done between Specialty Chemicals, Integrated PET and Fibers in 1Q25 to reflect business performance correctly. Since the impact is not material hence prior periods reclassifications are not done;

2. Starting from 1Q25, we have normalized weather-related disruptions into our adjusted financials, and all the prior periods are restated accordingly to reflect the correct business performances without weather-related events Source: IVL Analysis

© Indorama Ventures 9

CPET

3Q 2025 - Combined PET

Combined PET Adjusted EBITDA ($M)

71

221

49

191

4

1

4

-17%

QoQ 3Q25 vs 2Q25

260

YoY

EBITDA decline due to lower industry spreads, lower volumes due to MTBE TAR, weaker than usual seasonal PET demand, unplanned outages, higher energy prices and dollar weakening partially offset by asset

Integrated PET

Specialty Chemicals

3Q24 4Q24 1Q25 2Q25 3Q25

Specialty Chemicals: Adjusted EBITDA of

$16M, higher due to full quarter of NDC

campaign and improved PIA performance.

Reported EBITDA ($M) 219 166 116 165 143

Source: IVL Analysis

© Indorama Ventures 10